Atara Bio Announces Participation in Two Upcoming Immuno-Oncology Conferences Mar 28, 2016 4:05pm EDT
Atara Bio Receives EMA Orphan Drug Designation for Allogeneic Epstein-Barr Virus Specific Cytotoxic T-lymphocytes to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder Mar 23, 2016 9:15am EDT
Atara Bio Announces Collaborating Investigators to Present Data from a Late Breaking Abstract at the American Association for Cancer Research (AACR) Annual Meeting Mar 16, 2016 4:45pm EDT
Atara Bio Announces Fourth Quarter and Full Year 2015 Financial Results and Recent Highlights Mar 03, 2016 4:05pm EST
Atara Bio to Present at the Cowen and Company 36th Annual Health Care Conference Feb 29, 2016 8:00am EST
Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD) Feb 08, 2016 8:00am EST
Atara Bio Announces Results From the Phase 2 Proof-of-Concept PINTA 745 Clinical Trial for Protein Energy Wasting in Patients With End Stage Renal Disease Dec 14, 2015 6:00am EST
